Carlos L. Arteaga, M.D., a devoted cancer researcher and clinician, was named Director of the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern Medical Center in September 2017. He also serves as Associate Dean of Oncology Programs. Dr. Arteaga is internationally recognized for his work in laboratory-based translational research and advancing the care of breast cancer patients. The majority of Dr. Arteaga’s career has been as a physician-scientist in Medical Oncology at the Vanderbilt-Ingram Cancer Center of Vanderbilt University, where he served as Associate Director for Translational/Clinical Research and Director of the Center for Cancer Targeted Therapies. At Vanderbilt, he also led a successful translational research program that includes a National Cancer Institute/National Institutes of Health SPORE award in breast cancer. He is a member of the American Society for Clinical Investigation and the Association of American Physicians. He has earned numerous accolades from the American Cancer Society, the American Association for Cancer Research (AACR), Susan G. Komen for the Cure Foundation, and the American Society of Clinical Oncology. A former President of the AACR, he serves on the boards of advisors of several cancer centers and breast cancer programs. Dr. Arteaga earned his medical degree from Facultad de Ciencias Médicas at the Universidad de Guayaquil in Ecuador. He trained in Internal Medicine at Emory University and in Medical Oncology at the University of Texas Health Science Center at San Antonio.
- Medical School
- Universidad de Guayaquil, Ecuador (1980)
- Emory University School of Medicine (1984), Internal Medicine
- University of Texas Health Science Center, San Antonio (1988), Hematology Oncology
- A Phase Ib Study of Alpelisib (BYL719), a PI3Ka-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer.
- Mayer IA, Abramson VG, Formisano L, Balko JM, Estrada MV, Sanders ME, Juric D, Solit D, Berger MF, Won HH, Li Y, Cantley LC, Winer E, Arteaga CL Clin. Cancer Res. 2017 Jan 23 1 26-34
- Transcriptome- and proteome-oriented identification of dysregulated eIF4G, STAT3, and Hippo pathways altered by PIK3CA (H1047R) in HER2/ER-positive breast cancer.
- Cheng F, Zhao J, Hanker AB, Brewer MR, Arteaga CL, Zhao Z Breast Cancer Res. Treat. 2016 Dec 160 3 457-474
- PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment.
- Guerrero-Zotano A, Mayer IA, Arteaga CL Cancer Metastasis Rev. 2016 Dec 35 4 515-524
- Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.
- Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Blackwell KL, André F, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Petrakova K, Hart LL, Villanueva C, Chan A, Jakobsen E, Nusch A, Burdaeva O, Grischke EM, Alba E, Wist E, Marschner N, Favret AM, Yardley D, Bachelot T, Tseng LM, Blau S, Xuan F, Souami F, Miller M, Germa C, Hirawat S, O'Shaughnessy J N. Engl. J. Med. 2016 11 375 18 1738-1748
- The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer.
- Joseph JD, Darimont B, Zhou W, Arrazate A, Young A, Ingalla E, Walter K, Blake RA, Nonomiya J, Guan Z, Kategaya L, Govek SP, Lai AG, Kahraman M, Brigham D, Sensintaffar J, Lu N, Shao G, Qian J, Grillot K, Moon M, Prudente R, Bischoff E, Lee KJ, Bonnefous C, Douglas KL, Julien JD, Nagasawa JY, Aparicio A, Kaufman J, Haley B, Giltnane JM, Wertz IE, Lackner MR, Nannini MA, Sampath D, Schwarz L, Manning HC, Tantawy MN, Arteaga CL, Heyman RA, Rix PJ, Friedman L, Smith ND, Metcalfe C, Hager JH Elife 2016 Jul 5
- PIK3CA(H1047R)- and Her2-initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling.
- Cheng H, Liu P, Ohlson C, Xu E, Symonds L, Isabella A, Muller WJ, Lin NU, Krop IE, Roberts TM, Winer EP, Arteaga CL, Zhao JJ Oncogene 2016 Jun 35 23 2961-70
- Is There a Future for AKT Inhibitors in the Treatment of Cancer?
- Jansen VM, Mayer IA, Arteaga CL Clin. Cancer Res. 2016 Jun 22 11 2599-601
- Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence.
- Balko JM, Schwarz LJ, Luo N, Estrada MV, Giltnane JM, Dávila-González D, Wang K, Sánchez V, Dean PT, Combs SE, Hicks D, Pinto JA, Landis MD, Doimi FD, Yelensky R, Miller VA, Stephens PJ, Rimm DL, Gómez H, Chang JC, Sanders ME, Cook RS, Arteaga CL Sci Transl Med 2016 Apr 8 334 334ra53
- RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors.
- Loi S, Dushyanthen S, Beavis PA, Salgado R, Denkert C, Savas P, Combs S, Rimm DL, Giltnane JM, Estrada MV, Sánchez V, Sanders ME, Cook RS, Pilkinton MA, Mallal SA, Wang K, Miller VA, Stephens PJ, Yelensky R, Doimi FD, Gómez H, Ryzhov SV, Darcy PK, Arteaga CL, Balko JM Clin. Cancer Res. 2016 Mar 22 6 1499-509
- Systematic Prioritization of Druggable Mutations in ~5000 Genomes Across 16 Cancer Types Using a Structural Genomics-based Approach.
- Zhao J, Cheng F, Wang Y, Arteaga CL, Zhao Z Mol. Cell Proteomics 2016 Feb 15 2 642-56